ReviewClinical microbiology reviews2017
Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.
Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Does probiotic supplementation aid weight loss? A randomized, single-blind, placebo-controlled study with Bifidobacterium lactis BS01 and Lactobacillus acidophilus LA02 supplementation.Eating and weight disorders : EWD · 2021Trial
- Anti-Inflammatory Effects ofFood science & nutrition · 2026Article
- Expression of immune-related genes and possible regulatory mechanisms in ulcerative colitis.Frontiers in molecular biosciences · 2026Article
- Article
- The ameliorative effect of Lactiplantibacillus plantarum SCS2 on DSS-induced murine colitis.Archives of microbiology · 2025Article
- Lactobacillus paracasei Jlus66 relieves DSS-induced ulcerative colitis in a murine model by maintaining intestinal barrier integrity, inhibiting inflammation, and improving intestinal microbiota structure.European journal of nutrition · 2024Article
- Article
- Controlling the human microbiome.Cell systems · 2023Review
- The Mechanism of Important Components in Canine Fecal Microbiota Transplantation.Veterinary sciences · 2022Review
- Contribution of gut microbiota toward renal function in sepsis.Frontiers in microbiology · 2022Review
- Frontiers in antibiotic alternatives forWorld journal of gastroenterology · 2021Article
- Probiotics Improve Eating Disorders in Mandarin Fish (Microorganisms · 2021Article
- Combination of Enteral Nutrition and Probiotics Promote Recovery Following Ileal Pouch-Anal Anastomosis in Rats.Inflammation · 2021Article
- Linking Gut Microbiome and Lipid Metabolism: Moving beyond Associations.Metabolites · 2021Review
- The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease.Frontiers in nutrition · 2021Review
- Immunological design of commensal communities to treat intestinal infection and inflammation.PLoS pathogens · 2021Article
- The Preventive Effect ofOxidative medicine and cellular longevity · 2021Article
- Effect of Extracellular Vesicles Derived FromFrontiers in immunology · 2021Article
- Mucin-2 knockout is a model of intercellular junction defects, mitochondrial damage and ATP depletion in the intestinal epithelium.Scientific reports · 2020Article
- MICROBIOTA INSIGHTS IN CLOSTRIDIUM DIFFICILE INFECTION AND INFLAMMATORY BOWEL DISEASE.Gut microbes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Beneficial microorganisms hold promise for the treatment of numerous gastrointestinal diseases. The transfer of whole microbiota via fecal transplantation has already been shown to ameliorate the severity of diseases such as Clostridium difficile infection, inflammatory bowel disease, and others. However, the exact mechanisms of fecal microbiota transplant efficacy and the particular strains conferring this benefit are still unclear. Rationally designed combinations of microbial preparations may enable more efficient and effective treatment approaches tailored to particular diseases. Here we use an infectious disease, C. difficile infection, and an inflammatory disorder, the inflammatory bowel disease ulcerative colitis, as examples to facilitate the discussion of how microbial therapy might be rationally designed for specific gastrointestinal diseases. Fecal microbiota transplantation has already shown some efficacy in the treatment of both these disorders; detailed comparisons of studies evaluating commensal and probiotic organisms in the context of these disparate gastrointestinal diseases may shed light on potential protective mechanisms and elucidate how future microbial therapies can be tailored to particular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.